Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study
Floris J. Voskuil1,2,3, Steven J. de Jongh1,4, Wouter T.R. Hooghiemstra1,2,3, Matthijs D. Linssen5, Pieter J. Steinkamp2, Sebastiaan A. H. J. de Visscher1,2,3, Kees‐Pieter Schepman4, Sjoerd G. Elias6, Gert Jan Meersma1,2,3, Pascal Jonker1,2,3, Jan J. Doff7, Annelies Jorritsma‐Smit5, Wouter B. Nagengast1, Bert van der Vegt7, Dominic J. Robinson8, Gooitzen M. van Dam, Max J. H. Witjes4
1Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, the Netherlands
2 . Department of Surgery and Medical Imaging Center, University of Groningen, University Medical Center Groningen, the Netherlands
3Department of Oral & Maxillofacial Surgery, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen the Netherlands.
4Department of Oral & Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, the Netherlands
5Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, the Netherlands
6Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, the Netherlands
7. Department of Pathology & Medical Biology, University of Groningen, University Medical Center Groningen, the Netherlands
8. Center for Optical Diagnostics and Therapy, Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands